Search
osilodrostat (Isturisa)
Indicsations:
- treatment of Cushing's disease
Dosage:
- start 2 mg PO BID
- increase every 2 weeks up to 30 mg PO BID
Adverse effects:
- adrenal insufficiency, hypocortisolism
- headache
- nausea, vomiting
- fatigue
- edema
- QTc prolongation
- excess androgens
Mechanism of action:
- inhibits 11-beta-hydroxylase thus inhibits cortisol synthesis
General
heterocyclic compound, 2 rings
aromatic compound
nitrile
endocrine agent
Database Correlations
PUBCHEM cid=44139752
References
- FDA News Release. March 6, 2020
FDA Approves New Treatment for Adults with Cushing;s Disease.
https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-adults-cushings-disease